
Afatinib (Giotrif®) :
The 1st choice
in 1st-line
						
								Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
						demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
